Tracy M. Valorie
Directeur/Membre du Conseil chez SAMSARA VISION, INC.
Profil
Tracy M.
Valorie currently works at Samsara Vision, Inc., as Independent Director from 2021, Layerbio, Inc., as Director from 2020, PolyActiva Pty Ltd., as Non-Executive Director from 2020, Visus Therapeutics, Inc., as Director from 2021, Sprout Pharmaceuticals, Inc., as President, and TMV Associates LLC, as Owner from 2019.
Ms. Valorie also formerly worked at Glaucoma Foundation, as Director from 2009 to 2011, ARVO Foundation for Eye Research, as Director from 2009 to 2011, Bausch & Lomb, Inc., as Senior VP & GM-US Pharmaceutical & Surgical from 2012 to 2019, Bausch Health Cos., Inc., as VP-Marketing Pharmaceutical Ophthalmology, and Ophthalmic World Leaders, as Member from 2014 to 2018.
Ms. Valorie received her Masters Business Admin degree from Rensselaer Polytechnic Institute and undergraduate degree from the University of Connecticut.
Postes actifs de Tracy M. Valorie
| Sociétés | Poste | Début |
|---|---|---|
| SAMSARA VISION, INC. | Directeur/Membre du Conseil | 04/01/2021 |
Sprout Pharmaceuticals, Inc.
 Sprout Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sprout Pharmaceuticals, Inc. provides delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder. The company was founded by Cynthia E. Whitehead and Robert S. Whitehead on November 29, 2011 and is headquartered in Raleigh, NC. | President | - |
PolyActiva Pty Ltd.
 PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | 01/09/2020 |
Layerbio, Inc.
 Layerbio, Inc. Miscellaneous Commercial ServicesCommercial Services Layerbio, Inc. develops bio erodible sustained-release technology for use in standard intraocular lens in cataract surgery. The private company is based in Lexington, MA. The company was founded in 2013 by Kenneth J. Mandell, Paula Hammond. Kenneth J. Mandell has been the CEO since 2013. | Directeur/Membre du Conseil | 01/11/2020 |
Visus Therapeutics, Inc.
 Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Directeur/Membre du Conseil | 25/08/2021 |
| TMV Associates LLC | Corporate Officer/Principal | 01/07/2019 |
Anciens postes connus de Tracy M. Valorie
| Sociétés | Poste | Fin |
|---|---|---|
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Corporate Officer/Principal | 01/05/2019 |
| Ophthalmic World Leaders | Corporate Officer/Principal | 01/10/2018 |
| Glaucoma Foundation | Directeur/Membre du Conseil | 01/09/2011 |
| ░░░░ ░░░░░░░░░░ ░░░ ░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | - |
Formation de Tracy M. Valorie
| Rensselaer Polytechnic Institute | Masters Business Admin |
| University of Connecticut | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BAUSCH HEALTH COMPANIES INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
Samsara Vision, Inc.
 Samsara Vision, Inc. Medical SpecialtiesHealth Technology Samsara Vision, Inc. engages in the business of research, development, manufacturing, and marketing proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. It operates under the United States and Other geographical segments. The company was founded by Isaac Lipshitz, David Lifschitz, Yossi Gross, Boaz Lifschitz, and Eyal Lifschitz in 1997 and is headquartered in Far Hills, NJ. | Health Technology |
Layerbio, Inc.
Layerbio, Inc. Miscellaneous Commercial ServicesCommercial Services Layerbio, Inc. develops bio erodible sustained-release technology for use in standard intraocular lens in cataract surgery. The private company is based in Lexington, MA. The company was founded in 2013 by Kenneth J. Mandell, Paula Hammond. Kenneth J. Mandell has been the CEO since 2013. | Commercial Services |
| Glaucoma Foundation | |
Sprout Pharmaceuticals, Inc.
Sprout Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sprout Pharmaceuticals, Inc. provides delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder. The company was founded by Cynthia E. Whitehead and Robert S. Whitehead on November 29, 2011 and is headquartered in Raleigh, NC. | Health Technology |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
| ARVO Foundation for Eye Research | |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
| TMV Associates LLC | |
| Ophthalmic World Leaders |
